Currently Enrolling Trials

Intravitreous Anti-VEGF vs. Prompt Vitrectomy for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy (protocol AB)
For more information please email: lita@retinasanantonio.com or j.bermea@retinasanantonio.com
https://clinicaltrials.gov/ct2/show/NCT02858076

Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk (protocol W)
For more information please email: lita@retinasanantonio.com or j.bermea@retinasanantonio.com
https://clinicaltrials.gov/ct2/show/NCT02634333

A Phase IIa Trial of TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO): A Double-masked, Randomized Trial to Evaluate Efficacy and Tolerability.
For more information please email: j.bermea@retinasanantonio.com
https://clinicaltrials.gov/ct2/show/NCT03093701

The Correlation of Checkup Vision Assessment System to Standard In Office Visual Assessment (CLEAR)
For more information please email: lita@retinasanantonio.com or j.bermea@retinasanantonio.com

Wet Age-Related Macular Degeneration

  • Allergan 150998-005 – A Safety and Efficacy Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration (Now Enrolling)
  • OHR-1601 – A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration (Now Enrolling)
  • Iconic hI-con1 – A Phase 2 Randomized, Double-masked, Multicenter, Active-controlled Study Evaluating Administration of Repeated Intravitreal Doses of hI-con1™ in Patients with Choroidal Neovascularization Secondary to Age-related Macular Degeneration (Enrollment Closed)
  • Alcon RTH258 – A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 versus Aflibercept in Subjects with Neovascular Age-Related Macular Degeneration (Enrollment Closed)

Dry Age-Related Macular Degeneration with Geographic Atrophy

  • Alcon CLG561 – A randomized, multi-center, single masked, sham controlled, proof-of –concept study of intravitreal CLG561 as a monotherapy or in combination with LFG316 in patients with geographic atrophy (Now Enrolling)

Diabetic Retinopathy Clinical Research Network DRCR (Now Enrolling)

  • Protocol U – Short-term Evaluation of Combination Corticosteroid + Anti-VEGF Treatment for Persistent Central-Involved Diabetic Macular Edema Following Anti-VEGF Therapy
  • Protocol V – Treatment for Central-Involved Diabetic Macular Edema in Eyes with Very Good Visual Acuity
  • Protocol W – Intravitreous Anti-VEGF Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
  • Protocol AA — Peripheral Diabetic Retinopathy (DR) Lesions on Ultrawide-field Fundus Images and Risk of DR Worsening Over Time
  • Genes in Diabetic Retinopathy Project

Diabetic Retinopathy Clinical Research Network DRCR (Enrollment Closed)

  • Protocol S : Prompt Panretinal Photocoagulation Versus Intravitreal Ranibizumab with Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
  • Protocol T : Intravitreal Bevacizumab Compared with Intravitreal Ranibizumab for Diabetic Macular Edema

Retinal Vein Occlusion

  • SCORE2 – A Multicenter, Prospective, Randomized, Phase III, Non-Inferiority Trial of Eyes with Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Versus Intravitreal Aflibercept (Enrollment Closed)

Active Clinical Trials (Closed for enrollment)

A Two-Year, Randomized, Double-Masked, Multicenter, Three-Arm Study Comparing the Efficacy and Safety of RTH258 Versus Aflibercept in Subjects With Neovascular Age-Related Macular Degeneration (Alcon HAWK trial)
https://clinicaltrials.gov/ct2/show/NCT02307682

Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (Allergan CEDAR)
https://clinicaltrials.gov/ct2/show/NCT02462928

A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration (OHR 1601)
https://clinicaltrials.gov/ct2/show/NCT02727881

A randomized, multi-center, single masked, sham controlled, proof-of –concept study of intravitreal CLG561 as a monotherapy or in combination with LFG316 in patients with geographic atrophy (Alcon CLG561)
https://clinicaltrials.gov/ct2/show/NCT02515942

A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Pilot Study to Evaluate Effects of Emixustat Hydrochloride on Aqueous Humor Biomarkers Associated With Proliferative Diabetic Retinopathy
https://clinicaltrials.gov/ct2/show/NCT02753400

Peripheral Diabetic Retinopathy (DR) Lesions on Ultrawide-field Fundus Images and Risk of DR Worsening Over Time. (Protocol AA)
http://drcrnet.jaeb.org/Studies.aspx?RecID=239

Treatment for Central-Involved Diabetic Macular Edema in Eyes With Very Good Visual Acuity (Protocol V)
https://clinicaltrials.gov/ct2/show/NCT01909791

Study of COmparative Treatments for REtinal Vein Occlusion 2 [SCORE2]: a Multicenter, Prospective, Randomized Non-inferiority Trial of Eyes With Macular Edema Secondary to Central Retinal Vein Occlusion, Comparing Intravitreal Bevacizumab Every 4 Weeks With Intravitreal Aflibercept Every 4 Weeks.
https://clinicaltrials.gov/ct2/show/NCT01969708

Acucela

  • “Seattle” Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride

Diabetic Retinopathy Clinical Research Network DRCR Studies

  • Protocol “L”: Evaluation of Visual Acuity Measurements in Eyes with Diabetic Macular Edema
  • Protocol “N”: An Evaluation of Intravitreal Ranibizumab for Vitreous Hemorrhage due to Proliferative Diabetic Retinopathy
  • Protocol “P”: A pilot Study in Individuals with Center-Involved Diabetic Macular Edema Undergoing Cataract Surgery
  • Protocol “Q”: An Observational Study in Individuals with Diabetic Retinopathy Without Center-Involved DME Undergoing Cataract Surgery.

Quark

  • “MATISSE Study” PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)

Novartis

  • A 16 Week Evaluation of the Novartis Health Management Tool in Assessing Self-Test Visual Function in Patients with AMD treated with Lucentis

Thrombogenics

  • “TG-MV-006” A Randomized, Placebo Controlled, Double-Masked, Multicenter Trial of Micropalsmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion
  • “Oasis” A Randomized, Sham-Controlled, Double-Masked, Multicenter Study Evaluating Ocriplasmin Treatment for Symptomatic Vitreomacular Adhesion (VMT) Including Macular Hole.

Macusight

  • “DIAMOND Study” DR-002. A Phase 2, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injections of Sirolimus in Patients with Diabetic Macular Edema Secondary to Diabetic Retinopathy”
  • “Emerald Study” AMD-003. A Phase 2, Randomized, Masked, Controlled Clinical Study to Assess the Safety and Efficacy of Lucentis plus Sirolimus versus Lucentis Plus Placebo in Patients with Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.